Breakthrough cancer pain

Morphine remains gold standard in breakthrough cancer pain

BMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a3104 (Published 24 December 2008)
Cite this as: BMJ 2008;337:a3104

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Vicente Ruiz-Garcia1,
  2. Eduardo Lopez-Briz1
  1. 1Home Hospitalisation Unit, HU La Fe, 46014 Valencia, Spain
  1. ruiz_vicgar{at}redcaspe.org

    Although Davies and colleagues argue that little evidence supports the unlicensed use of oral morphine,1 morphine remains the gold standard in cancer pain. Licensed or unlicensed use is a transient status, especially in palliative care. Little evidence may support the use of oral …

    Get access to this article and all of bmj.com for the next 14 days

    Sign up for a 14 day free trial today

    Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL